Taysha launches $75M public offering; reports positive clinical data in Rett syndrome

Taysha Gene Therapies, Inc.

Commenced underwritten public offering of up to $75M in common stock and pre-funded warrants; underwriters have 30-day option for additional 15%.
TSHA-102 in Rett syndrome shows sustained improvements in motor, hand function, and seizure reduction in two adult patients at 52 and 36 weeks.
IDMC approved dose escalation to cohort 2; first high-dose patient dosed in Q2 2024; initial data from cohort 2 expected H2 2024.
Received RMAT designation from FDA for TSHA-102 in April 2024, providing expedited development pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.